Dexcom +5% as FDA approves pediatric use of glucose monitoring system


DexCom (DXCM+5.1% AH after the FDA approves pediatric use of the company’s G4 Platinum continuous glucose monitoring system.

The G4 Platinum System, which monitors blood glucose levels in people with diabetes, already had been approved for patients age 18 and older.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs